Sara Zanivan, PHD
Department of Experimental Therapeutics, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Scientific Director Proteomics Core, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Honorary Professor, School of Cancer Sciences, University of Glasgow
Research Interests
The research of my group aims to understand the molecular mechanisms that underpin how cancer associated fibroblasts (CAFs) influence cancer pathology through interacting with other cell types and by modifying the tumour microenvironment. A major focus of our research is cell metabolism and how we can modulate it in CAFs to create an anti-tumour microenvironment and new vulnerabilities for anti-cancer therapies. The overarching goal of our research is to find ways to target CAFs to treat cancer patients effectively. My group also develops mass spectrometry (MS) proteomic approaches for cancer research. Recently, we have developed a line of clinical research aimed at the discovery of circulating biomarkers for early detection and to predict risk of cancer.
Education & Training
Degree-Granting Education
| 2006 | University of Torino, Candiolo Cancer Institute IRCCS, Candiolo, Torino, IT, Complex Systems Applied to Post-Genomic Biology, Ph.D |
| 2002 | University of Torino, Candiolo Cancer Institute IRCCS, Candiolo, Torino, IT, Bioinformatics, Masters |
| 2001 | University of Torino, Candiolo Cancer Institute IRCCS, Candiolo, Torino, IT, Biology, Masters |
Postgraduate Training
| 2007-2010 | Postdoctoral Fellow, Max-Planck Institute for Biochemistry |
| 2002-2006 | Ph.D. Student, University of Torino, Candiolo Cancer Insitute IRCCS |
Experience & Service
Academic Appointments
Professor, School of Cancer Sciences, University of Glasgow, 2019 - 2024
Head, Proteomics Advanced Technology Facility, Cancer Research UK Scotland Institute, 2015 - 2024
Senior Lecturer, School of Cancer Sciences, University of Glasgow, 2013 - 2019
Head, Laboratory of Tumor Microenvironment and Proteomics, Cancer Research UK Scotland Institute, 2010 - 2024
Institutional Committee Activities
Member, Science Strategy Committee, 2023 - 2024
Chair, CRUK Expert Review Early Detection & Diagnosis Panel, 2023 - 2023
Member, Scientific Advisory Board, 2022 - 2022
Member, CRUK Early Detection & Diagnosis research committee, 2020 - 2020
Member, Academic Board, Ph.D. Program for Pharmacological Sciences, 2020 - 2020
Member, Scientific Advisory Board for Glasgow Polyomics, 2020 - 2024
Panel Member, Irish Cancer Society Fellowship, 2019 - 2019
Member and Chair, CRUK Research Travel Awards, 2015 - 2019
Panel Member, Evaluation panel for the Head of Proteomics of the Turku Proteomics Facility, 2015 - 2015
Member, Board of Directors, 2012 - 2024
Honors & Awards
| Emerging Investigator by the EMBO Cancer Proteomics | |
| CRUK Conference and Meeting Award for EuPA meeting, Cancer Research UK | |
| CRUK Conference and Meeting Award for BSPR meeting, Cancer Research UK | |
| CRUK Conference and Meeting Award for BSPR meeting, Cancer Research UK | |
| Elected Lecturer for the British Society Proteome Research (BSPR) |
Selected Publications
Peer-Reviewed Articles
- Singh SP, Smyth DJ, Cunningham KT, Mukundan A, Byeon CH, Hinck CS, White MPJ, Ciancia C, Wasowska N, Sanders A, Jin R, White RF, Lilla S, Zanivan S, Schoenherr C, Inman GJ, van Dinther M, Ten Dijke P, Hinck AP, Maizels RM. The TGF-beta mimic TGM4 achieves cell specificity through combinatorial surface co-receptor binding. EMBO Rep None(None):None, 2024. PMID: 39609640.
- Ackermann T, Shokry E, Deshmukh R, Anand J, Galbraith LCA, Mitchell L, Rodriguez-Blanco G, Villar VH, Sterken BA, Nixon C, Zanivan S, Blyth K, Sumpton D, Tardito S. Breast cancer secretes anti-ferroptotic MUFAs and depends on selenoprotein synthesis for metastasis. EMBO Mol Med 16(11):2749-2774, 2024. PMID: 39433871.
- Mahmood M, Liu EM, Shergold AL, Tolla E, Tait-Mulder J, Huerta-Uribe A, Shokry E, Young AL, Lilla S, Kim M, Park T, Boscenco S, Manchon JL, Rodriguez-Antona C, Walters RC, Springett RJ, Blaza JN, Mitchell L, Blyth K, Zanivan S, Sumpton D, Roberts EW, Reznik E, Gammage PA. Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma. Nat Cancer 5(4):659-672, 2024. PMID: 38286828.
- Sanchez-Lopez I, Orantos-Aguilera Y, Pozo-Guisado E, Alvarez-Barrientos A, Lilla S, Zanivan S, Lachaud C, Martin-Romero FJ. STIM1 translocation to the nucleus protects cells from DNA damage. Nucleic Acids Res 52(5):2389-2415, 2024. PMID: 38224453.
- Santi A, Kay EJ, Neilson LJ, McGarry L, Lilla S, Mullin M, Paul NR, Fercoq F, Koulouras G, Rodriguez Blanco G, Athineos D, Mason S, Hughes M, Thomson G, Kieffer Y, Nixon C, Blyth K, Mechta-Grigoriou F, Carlin LM, Zanivan S. Cancer-associated fibroblasts produce matrix-bound vesicles that influence endothelial cell function. Sci Signal 17(827):eade0580, 2024. PMID: 38470957.
- Vringer E, Heilig R, Riley JS, Black A, Cloix C, Skalka G, Montes-Gomez AE, Aguado A, Lilla S, Walczak H, Gyrd-Hansen M, Murphy DJ, Huang DT, Zanivan S, Tait SW. Mitochondrial outer membrane integrity regulates a ubiquitin-dependent and NF-kappaB-mediated inflammatory response. EMBO J 43(6):904-930, 2024. PMID: 38337057.
- Dawson A, Zarou MM, Prasad B, Bittencourt-Silvestre J, Zerbst D, Himonas E, Hsieh YC, van Loon I, Blanco GR, Ianniciello A, Kerekes Z, Krishnan V, Agarwal P, Almasoudi H, McCluskey L, Hopcroft LEM, Scott MT, Baquero P, Dunn K, Vetrie D, Copland M, Bhatia R, Coffelt SB, Tiong OS, Wheadon H, Zanivan S, Kirschner K, Helgason GV. Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche. Nat Commun 15(1):1090, 2024. PMID: 38316788.
- Neilson LJ, Cartwright D, Risteli M, Jokinen EM, McGarry L, Sandvik T, Nikolatou K, Hodge K, Atkinson S, Vias M, Kay EJ, Brenton JD, Carlin LM, Bryant DM, Salo T, Zanivan S. Omentum-derived matrix enables the study of metastatic ovarian cancer and stromal cell functions in a physiologically relevant environment. Matrix Biol Plus 19-20(None):100136, 2023. PMID: 38223308.
- Nikolatou K, Sandilands E, Roman-Fernandez A, Cumming EM, Freckmann E, Lilla S, Buetow L, McGarry L, Neilson M, Shaw R, Strachan D, Miller C, Huang DT, McNeish IA, Norman JC, Zanivan S, Bryant DM. PTEN deficiency exposes a requirement for an ARF GTPase module for integrin-dependent invasion in ovarian cancer. EMBO J 42(18):e113987, 2023. PMID: 37577760.
- Subramaniam G, Schleicher K, Kovanich D, Zerio A, Folkmanaite M, Chao YC, Surdo NC, Koschinski A, Hu J, Scholten A, Heck AJR, Ercu M, Sholokh A, Park KC, Klussmann E, Meraviglia V, Bellin M, Zanivan S, Hester S, Mohammed S, Zaccolo M. Integrated Proteomics Unveils Nuclear PDE3A2 as a Regulator of Cardiac Myocyte Hypertrophy. Circ Res 132(7):828-848, 2023. PMID: 36883446.
- Altea-Manzano P, Doglioni G, Liu Y, Cuadros AM, Nolan E, Fernandez-Garcia J, Wu Q, Planque M, Laue KJ, Cidre-Aranaz F, Liu XZ, Marin-Bejar O, Van Elsen J, Vermeire I, Broekaert D, Demeyer S, Spotbeen X, Idkowiak J, Montagne A, Demicco M, Alkan HF, Rabas N, Riera-Domingo C, Richard F, Geukens T, De Schepper M, Leduc S, Hatse S, Lambrechts Y, Kay EJ, Lilla S, Alekseenko A, Geldhof V, Boeckx B, de la Calle Arregui C, Floris G, Swinnen JV, Marine JC, Lambrechts D, Pelechano V, Mazzone M, Zanivan S, Cools J, Wildiers H, Baud V, Grunewald TGP, Ben-David U, Desmedt C, Malanchi I, Fendt SM. A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-kappaB signaling. Nat Cancer 4(3):344-364, 2023. PMID: 36732635.
- Schmidt T, Dabrowska A, Waldron JA, Hodge K, Koulouras G, Gabrielsen M, Munro J, Tack DC, Harris G, McGhee E, Scott D, Carlin LM, Huang D, Le Quesne J, Zanivan S, Wilczynska A, Bushell M. eIF4A1-dependent mRNAs employ purine-rich 5'UTR sequences to activate localised eIF4A1-unwinding through eIF4A1-multimerisation to facilitate translation. Nucleic Acids Res 51(4):1859-1879, 2023. PMID: 36727461.
- Roman-Fernandez A, Mansour MA, Kugeratski FG, Anand J, Sandilands E, Galbraith L, Rakovic K, Freckmann EC, Cumming EM, Park J, Nikolatou K, Lilla S, Shaw R, Strachan D, Mason S, Patel R, McGarry L, Katoch A, Campbell KJ, Nixon C, Miller CJ, Leung HY, Le Quesne J, Norman JC, Zanivan S, Blyth K, Bryant DM. Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function. Sci Adv 9(5):eabq1858, 2023. PMID: 36735782.
- McGarry DJ, Castino G, Lilla S, Carnet A, Kelly L, Micovic K, Zanivan S, Olson MF. MICAL1 activation by PAK1 mediates actin filament disassembly. Cell Rep 41(1):111442, 2022. PMID: 36198272.
- Gioelli N, Neilson LJ, Wei N, Villari G, Chen W, Kuhle B, Ehling M, Maione F, Willox S, Brundu S, Avanzato D, Koulouras G, Mazzone M, Giraudo E, Yang XL, Valdembri D, Zanivan S, Serini G. Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability. Nat Commun 13(1):4188, 2022. PMID: 35858913.
- Baudot AD, Wang VM, Leach JD, O'Prey J, Long JS, Paulus-Hock V, Lilla S, Thomson DM, Greenhorn J, Ghaffar F, Nixon C, Helfrich MH, Strathdee D, Pratt J, Marchesi F, Zanivan S, Ryan KM. Glycan degradation promotes macroautophagy. Proc Natl Acad Sci U S A 119(26):e2111506119, 2022. PMID: 35737835.
- Narva E, Taskinen ME, Lilla S, Isomursu A, Pietila M, Weltner J, Isola J, Sihto H, Joensuu H, Zanivan S, Norman J, Ivaska J. MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels. iScience 25(6):104459, 2022. PMID: 35677646.
- Kay EJ, Paterson K, Riera-Domingo C, Sumpton D, Dabritz JHM, Tardito S, Boldrini C, Hernandez-Fernaud JR, Athineos D, Dhayade S, Stepanova E, Gjerga E, Neilson LJ, Lilla S, Hedley A, Koulouras G, McGregor G, Jamieson C, Johnson RM, Park M, Kirschner K, Miller C, Kamphorst JJ, Loayza-Puch F, Saez-Rodriguez J, Mazzone M, Blyth K, Zagnoni M, Zanivan S. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. Nat Metab 4(6):693-710, 2022. PMID: 35760868.
- Salji MJ, Blomme A, Dabritz JHM, Repiscak P, Lilla S, Patel R, Sumpton D, van den Broek NJF, Daly R, Zanivan S, Leung HY. Multi-omics & pathway analysis identify potential roles for tumor N-acetyl aspartate accumulation in murine models of castration-resistant prostate cancer. iScience 25(4):104056, 2022. PMID: 35345457.
- Blomme A, Peter C, Mui E, Rodriguez Blanco G, An N, Mason LM, Jamieson LE, McGregor GH, Lilla S, Ntala C, Patel R, Thiry M, Kung SHY, Leclercq M, Ford CA, Rushworth LK, McGarry DJ, Mason S, Repiscak P, Nixon C, Salji MJ, Markert E, MacKay GM, Kamphorst JJ, Graham D, Faulds K, Fazli L, Gleave ME, Avezov E, Edwards J, Yin H, Sumpton D, Blyth K, Close P, Murphy DJ, Zanivan S, Leung HY. THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Mol Med 14(3):e14764, 2022. PMID: 35014179.
- Marco S, Neilson M, Moore M, Perez-Garcia A, Hall H, Mitchell L, Lilla S, Blanco GR, Hedley A, Zanivan S, Norman JC. Nuclear-capture of endosomes depletes nuclear G-actin to promote SRF/MRTF activation and cancer cell invasion. Nat Commun 12(1):6829, 2021. PMID: 34819513.
- Gillen SL, Giacomelli C, Hodge K, Zanivan S, Bushell M, Wilczynska A. Differential regulation of mRNA fate by the human Ccr4-Not complex is driven by coding sequence composition and mRNA localization. Genome Biol 22(1):284, 2021. PMID: 34615539.
- Martinez RS, Salji MJ, Rushworth L, Ntala C, Rodriguez Blanco G, Hedley A, Clark W, Peixoto P, Hervouet E, Renaude E, Kung SHY, Galbraith LCA, Nixon C, Lilla S, MacKay GM, Fazli L, Gaughan L, Sumpton D, Gleave ME, Zanivan S, Blomme A, Leung HY. SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer. Cancer Res 81(13):3664-3678, 2021. PMID: 33985973.
- Kugeratski FG, Hodge K, Lilla S, McAndrews KM, Zhou X, Hwang RF, Zanivan S, Kalluri R. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. Nat Cell Biol 23(6):631-641, 2021. PMID: 34108659.
- Budden T, Gaudy-Marqueste C, Porter A, Kay E, Gurung S, Earnshaw CH, Roeck K, Craig S, Traves V, Krutmann J, Muller P, Motta L, Zanivan S, Malliri A, Furney SJ, Nagore E, Viros A. Ultraviolet light-induced collagen degradation inhibits melanoma invasion. Nat Commun 12(1):2742, 2021. PMID: 33980846.
- Nacke M, Sandilands E, Nikolatou K, Roman-Fernandez A, Mason S, Patel R, Lilla S, Yelland T, Galbraith LCA, Freckmann EC, McGarry L, Morton JP, Shanks E, Leung HY, Markert E, Ismail S, Zanivan S, Blyth K, Bryant DM. An ARF GTPase module promoting invasion and metastasis through regulating phosphoinositide metabolism. Nat Commun 12(1):1623, 2021. PMID: 33712589.
- Ahmed SF, Buetow L, Gabrielsen M, Lilla S, Sibbet GJ, Sumpton D, Zanivan S, Hedley A, Clark W, Huang DT. E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis. Oncogene 40(12):2149-2164, 2021. PMID: 33627783.
- Phatak V, von Grabowiecki Y, Janus J, Officer L, Behan C, Aschauer L, Pinon L, Mackay H, Zanivan S, Norman JC, Kelly M, Le Quesne J, Muller PAJ. Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane. Cell Death Dis 12(2):207, 2021. PMID: 33627632.
- Unbekandt M, Lilla S, Zanivan S, Olson MF. The CDC42 effector protein MRCKbeta autophosphorylates on Threonine 1108. Small GTPases 11(6):451-460, 2020. PMID: 30667325.
- Lobo MJ, Reverte-Salisa L, Chao YC, Koschinski A, Gesellchen F, Subramaniam G, Jiang H, Pace S, Larcom N, Paolocci E, Pfeifer A, Zanivan S, Zaccolo M. Phosphodiesterase 2A2 regulates mitochondria clearance through Parkin-dependent mitophagy. Commun Biol 3(1):596, 2020. PMID: 33087821.
- Ahmed SF, Buetow L, Gabrielsen M, Lilla S, Chatrin C, Sibbet GJ, Zanivan S, Huang DT. DELTEX2 C-terminal domain recognizes and recruits ADP-ribosylated proteins for ubiquitination. Sci Adv 6(34):None, 2020. PMID: 32937373.
- Taskinen ME, Narva E, Conway JRW, Hinojosa LS, Lilla S, Mai A, De Franceschi N, Elo LL, Grosse R, Zanivan S, Norman JC, Ivaska J. MASTL promotes cell contractility and motility through kinase-independent signaling. J Cell Biol 219(6):None, 2020. PMID: 32311005.
- Blomme A, Ford CA, Mui E, Patel R, Ntala C, Jamieson LE, Planque M, McGregor GH, Peixoto P, Hervouet E, Nixon C, Salji M, Gaughan L, Markert E, Repiscak P, Sumpton D, Blanco GR, Lilla S, Kamphorst JJ, Graham D, Faulds K, MacKay GM, Fendt SM, Zanivan S, Leung HY. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nat Commun 11(1):2508, 2020. PMID: 32427840.
- Oizel K, Tait-Mulder J, Fernandez-de-Cossio-Diaz J, Pietzke M, Brunton H, Lilla S, Dhayade S, Athineos D, Blanco GR, Sumpton D, Mackay GM, Blyth K, Zanivan SR, Meiser J, Vazquez A. Formate induces a metabolic switch in nucleotide and energy metabolism. Cell Death Dis 11(5):310, 2020. PMID: 32366892.
- Cao X, Lilla S, Cao Z, Pringle MA, Oka OBV, Robinson PJ, Szmaja T, van Lith M, Zanivan S, Bulleid NJ. The mammalian cytosolic thioredoxin reductase pathway acts via a membrane protein to reduce ER-localised proteins. J Cell Sci 133(8):None, 2020. PMID: 32184267.
- Loveridge CJ, Slater S, Campbell KJ, Nam NA, Knight J, Ahmad I, Hedley A, Lilla S, Repiscak P, Patel R, Salji M, Fleming J, Mitchell L, Nixon C, Strathdee D, Neilson M, Ntala C, Bryson S, Zanivan S, Edwards J, Robson CN, Goodyear CS, Blyth K, Leung HY. BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene 39(8):1797-1806, 2020. PMID: 31740786.
- Tait-Mulder J, Hodge K, Sumpton D, Zanivan S, Vazquez A. The conversion of formate into purines stimulates mTORC1 leading to CAD-dependent activation of pyrimidine synthesis. Cancer Metab 8(None):20, 2020. PMID: 32974014.
- Wilczynska A, Gillen SL, Schmidt T, Meijer HA, Jukes-Jones R, Langlais C, Kopra K, Lu WT, Godfrey JD, Hawley BR, Hodge K, Zanivan S, Cain K, Le Quesne J, Bushell M. eIF4A2 drives repression of translation at initiation by Ccr4-Not through purine-rich motifs in the 5'UTR. Genome Biol 20(1):262, 2019. PMID: 31791371.
- Ferraro DA, Patella F, Zanivan S, Donato C, Aceto N, Giannotta M, Dejana E, Diepenbruck M, Christofori G, Buess M. Endothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cells. BMC Cancer 19(1):312, 2019. PMID: 30947697.
- Kugeratski FG, Atkinson SJ, Neilson LJ, Lilla S, Knight JRP, Serneels J, Juin A, Ismail S, Bryant DM, Markert EK, Machesky LM, Mazzone M, Sansom OJ, Zanivan S. Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. Sci Signal 12(567):None, 2019. PMID: 30723174.
- Whitelaw JA, Lilla S, Paul NR, Fort L, Zanivan S, Machesky LM. CYRI/ Fam49 Proteins Represent a New Class of Rac1 Interactors. Commun Integr Biol 12(1):112-118, 2019. PMID: 31413787.
- Novo D, Heath N, Mitchell L, Caligiuri G, MacFarlane A, Reijmer D, Charlton L, Knight J, Calka M, McGhee E, Dornier E, Sumpton D, Mason S, Echard A, Klinkert K, Secklehner J, Kruiswijk F, Vousden K, Macpherson IR, Blyth K, Bailey P, Yin H, Carlin LM, Morton J, Zanivan S, Norman JC. Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nat Commun 9(1):5069, 2018. PMID: 30498210.
- Fort L, Batista JM, Thomason PA, Spence HJ, Whitelaw JA, Tweedy L, Greaves J, Martin KJ, Anderson KI, Brown P, Lilla S, Neilson MP, Tafelmeyer P, Zanivan S, Ismail S, Bryant DM, Tomkinson NCO, Chamberlain LH, Mastick GS, Insall RH, Machesky LM. Fam49/CYRI interacts with Rac1 and locally suppresses protrusions. Nat Cell Biol 20(10):1159-1171, 2018. PMID: 30250061.
- Dandoulaki M, Petsalaki E, Sumpton D, Zanivan S, Zachos G. Src activation by Chk1 promotes actin patch formation and prevents chromatin bridge breakage in cytokinesis. J Cell Biol 217(9):3071-3089, 2018. PMID: 29954829.
- Port J, Muthalagu N, Raja M, Ceteci F, Monteverde T, Kruspig B, Hedley A, Kalna G, Lilla S, Neilson L, Brucoli M, Gyuraszova K, Tait-Mulder J, Mezna M, Svambaryte S, Bryson A, Sumpton D, McVie A, Nixon C, Drysdale M, Esumi H, Murray GI, Sansom OJ, Zanivan SR, Murphy DJ. Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress. Cancer Discov 8(5):632-647, 2018. PMID: 29500295.
- van der Reest J, Lilla S, Zheng L, Zanivan S, Gottlieb E. Proteome-wide analysis of cysteine oxidation reveals metabolic sensitivity to redox stress. Nat Commun 9(1):1581, 2018. PMID: 29679077.
- Kugeratski FG, Batista M, Lima CVP, Neilson LJ, da Cunha ES, de Godoy LM, Zanivan S, Krieger MA, Marchini FK. Mitogen-Activated Protein Kinase Kinase 5 Regulates Proliferation and Biosynthetic Processes in Procyclic Forms of Trypanosoma brucei. J Proteome Res 17(1):108-118, 2018. PMID: 29043805.
- van den Eshof BL, Hoogendijk AJ, Simpson PJ, van Alphen FPJ, Zanivan S, Mertens K, Meijer AB, van den Biggelaar M. Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics. Arterioscler Thromb Vasc Biol 37(10):1891-1902, 2017. PMID: 28818855.
- Reid SE, Kay EJ, Neilson LJ, Henze AT, Serneels J, McGhee EJ, Dhayade S, Nixon C, Mackey JB, Santi A, Swaminathan K, Athineos D, Papalazarou V, Patella F, Roman-Fernandez A, ElMaghloob Y, Hernandez-Fernaud JR, Adams RH, Ismail S, Bryant DM, Salmeron-Sanchez M, Machesky LM, Carlin LM, Blyth K, Mazzone M, Zanivan S. Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. EMBO J 36(16):2373-2389, 2017. PMID: 28694244.
- Diaz-Vera J, Palmer S, Hernandez-Fernaud JR, Dornier E, Mitchell LE, Macpherson I, Edwards J, Zanivan S, Norman JC. A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. J Cell Sci 130(4):697-711, 2017. PMID: 28062852.
- Hernandez-Fernaud JR, Ruengeler E, Casazza A, Neilson LJ, Pulleine E, Santi A, Ismail S, Lilla S, Dhayade S, MacPherson IR, McNeish I, Ennis D, Ali H, Kugeratski FG, Al Khamici H, van den Biggelaar M, van den Berghe PV, Cloix C, McDonald L, Millan D, Hoyle A, Kuchnio A, Carmeliet P, Valenzuela SM, Blyth K, Yin H, Mazzone M, Norman JC, Zanivan S. Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nat Commun 8(None):14206, 2017. PMID: 28198360.
- Patella F, Neilson LJ, Athineos D, Erami Z, Anderson KI, Blyth K, Ryan KM, Zanivan S. In-Depth Proteomics Identifies a Role for Autophagy in Controlling Reactive Oxygen Species Mediated Endothelial Permeability. J Proteome Res 15(7):2187-97, 2016. PMID: 27246970.
- Clarke CJ, Berg TJ, Birch J, Ennis D, Mitchell L, Cloix C, Campbell A, Sumpton D, Nixon C, Campbell K, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Jones JL, Haywood L, Pulleine E, Yin H, Strathdee D, Sansom O, Blyth K, McNeish I, Zanivan S, Reynolds AR, Norman JC. The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis. Curr Biol 26(6):755-65, 2016. PMID: 26948875.
- Deschoemaeker S, Di Conza G, Lilla S, Martin-Perez R, Mennerich D, Boon L, Hendrikx S, Maddocks OD, Marx C, Radhakrishnan P, Prenen H, Schneider M, Myllyharju J, Kietzmann T, Vousden KH, Zanivan S, Mazzone M. PHD1 regulates p53-mediated colorectal cancer chemoresistance. EMBO Mol Med 7(10):1350-65, 2015. PMID: 26290450.
- Kuchnio A, Moens S, Bruning U, Kuchnio K, Cruys B, Thienpont B, Broux M, Ungureanu AA, Leite de Oliveira R, Bruyere F, Cuervo H, Manderveld A, Carton A, Hernandez-Fernaud JR, Zanivan S, Bartic C, Foidart JM, Noel A, Vinckier S, Lambrechts D, Dewerchin M, Mazzone M, Carmeliet P. The Cancer Cell Oxygen Sensor PHD2 Promotes Metastasis via Activation of Cancer-Associated Fibroblasts. Cell Rep 12(6):992-1005, 2015. PMID: 26235614.
- Patella F, Schug ZT, Persi E, Neilson LJ, Erami Z, Avanzato D, Maione F, Hernandez-Fernaud JR, Mackay G, Zheng L, Reid S, Frezza C, Giraudo E, Fiorio Pla A, Anderson K, Ruppin E, Gottlieb E, Zanivan S. Proteomics-based metabolic modeling reveals that fatty acid oxidation (FAO) controls endothelial cell (EC) permeability. Mol Cell Proteomics 14(3):621-34, 2015. PMID: 25573745.
- Guo Z, Neilson LJ, Zhong H, Murray PS, Zanivan S, Zaidel-Bar R. E-cadherin interactome complexity and robustness resolved by quantitative proteomics. Sci Signal 7(354):rs7, 2014. PMID: 25468996.
- van den Biggelaar M, Hernandez-Fernaud JR, van den Eshof BL, Neilson LJ, Meijer AB, Mertens K, Zanivan S. Quantitative phosphoproteomics unveils temporal dynamics of thrombin signaling in human endothelial cells. Blood 123(12):e22-36, 2014. PMID: 24501219.
- Reid S, Hernandez-Fernaud JR, Zanivan S. In vivo quantitative proteomics for the study of oncometabolism. Methods Enzymol 543(None):235-59, 2014. PMID: 24924136.
- Zanivan S, Maione F, Hein MY, Hernandez-Fernaud JR, Ostasiewicz P, Giraudo E, Mann M. SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers. Mol Cell Proteomics 12(12):3599-611, 2013. PMID: 23979707.
- Neuhauser N, Nagaraj N, McHardy P, Zanivan S, Scheltema R, Cox J, Mann M. High performance computational analysis of large-scale proteome data sets to assess incremental contribution to coverage of the human genome. J Proteome Res 12(6):2858-68, 2013. PMID: 23611042.
- Schiller HB, Hermann MR, Polleux J, Vignaud T, Zanivan S, Friedel CC, Sun Z, Raducanu A, Gottschalk KE, Thery M, Mann M, Fassler R. beta1- and alphav-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based microenvironments. Nat Cell Biol 15(6):625-36, 2013. PMID: 23708002.
- Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT, Noll JE, Coffill CR, Lane DP, Sansom OJ, Neilsen PM, Norman JC, Vousden KH. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 32(10):1252-65, 2013. PMID: 22580601.
- Zanivan S, Meves A, Behrendt K, Schoof EM, Neilson LJ, Cox J, Tang HR, Kalna G, van Ree JH, van Deursen JM, Trempus CS, Machesky LM, Linding R, Wickstrom SA, Fassler R, Mann M. In vivo SILAC-based proteomics reveals phosphoproteome changes during mouse skin carcinogenesis. Cell Rep 3(2):552-66, 2013. PMID: 23375375.
- Azimifar SB, Bottcher RT, Zanivan S, Grashoff C, Kruger M, Legate KR, Mann M, Fassler R. Induction of membrane circular dorsal ruffles requires co-signalling of integrin-ILK-complex and EGF receptor. J Cell Sci 125(Pt 2):435-48, 2012. PMID: 22357970.
- Zanivan S, Krueger M, Mann M. In vivo quantitative proteomics: the SILAC mouse. Methods Mol Biol 757(None):435-50, 2012. PMID: 21909926.
- Meves A, Geiger T, Zanivan S, DiGiovanni J, Mann M, Fassler R. Beta1 integrin cytoplasmic tyrosines promote skin tumorigenesis independent of their phosphorylation. Proc Natl Acad Sci U S A 108(37):15213-8, 2011. PMID: 21876123.
- Kruger M, Moser M, Ussar S, Thievessen I, Luber CA, Forner F, Schmidt S, Zanivan S, Fassler R, Mann M. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 134(2):353-64, 2008. PMID: 18662549.
- Zanivan S, Corà D, Caselle M, Bussolino F. VRG: A database of vascular dysfunctions related genes. Computers & Mathematics with Applications 55(5):1068-1073, 2008. PMID: None.
- Zanivan S, Cascone I, Peyron C, Molineris I, Marchio S, Caselle M, Bussolino F. A new computational approach to analyze human protein complexes and predict novel protein interactions. Genome Biol 8(12):R256, 2007. PMID: 18053208.
- Parsons-Wingerter P, Kasman IM, Norberg S, Magnussen A, Zanivan S, Rissone A, Baluk P, Favre CJ, Jeffry U, Murray R, McDonald DM. Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am J Pathol 167(1):193-211, 2005. PMID: 15972964.
- Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, Zammataro L, Primo L, Tamagnone L, Logan M, Tessier-Lavigne M, Taniguchi M, Puschel AW, Bussolino F. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424(6947):391-7, 2003. PMID: 12879061.
Invited Articles
- Kay EJ, Zanivan S. Bicarbonate transport as regulator of antitumour immunity in pancreatic cancer. Mol Oncol 17(4):541-544, 2023. PMID: 36807529.
- Kay EJ, Zanivan S. Methylmalonic acid: an age-related metabolite that drives tumour aggressiveness. Nat Metab 4(4):412-413, 2022. PMID: 35361957.
- Kay EJ, Zanivan S. Two opposing sub-populations of fibroblasts decide progression of pancreatic cancer. Cancer Cell 39(9):1175-1177, 2021. PMID: 34520729.
- Norman J, Zanivan S. Chloride intracellular channel 3: A secreted pro-invasive oxidoreductase. Cell Cycle 16(21):1993-1994, 2017. PMID: 28933594.
- Reid SE, Zanivan S. Tumor stiffness extends its grip on the metastatic microenvironment. Mol Cell Oncol 4(6):e1372866, 2017. PMID: 29209654.
Other Articles
- Kay EJ, Zanivan S, Rufini A Proline metabolism shapes the tumor microenvironment: from collagen deposition to immune evasion. Curr Opin Biotechnol 84(None):103011, 2023. PMID: 37864905.
- Kugeratski FG, Santi A, Zanivan S Extracellular vesicles as central regulators of blood vessel function in cancer. Sci Signal 15(753):eaaz4742, 2022. PMID: 36166511.
- Kay EJ, Zanivan S Metabolic pathways fuelling protumourigenic cancer-associated fibroblast functions. Current Opinion in Systems Biology 28(None):100377, 2021. PMID: None.
- Paterson K, Zanivan S, Glasspool R, Coffelt SB, Zagnoni M Microfluidic technologies for immunotherapy studies on solid tumours. Lab Chip 21(12):2306-2329, 2021. PMID: 34085677.
- Domen A, Quatannens D, Zanivan S, Deben C, Van Audenaerde J, Smits E, Wouters A, Lardon F, Roeyen G, Verhoeven Y, Janssens A, Vandamme T, van Dam P, Peeters M, Prenen H Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers (Basel) 13(5):None, 2021. PMID: 33673405.
- Kilonsky DJ, Abdel Aziz, AK, Abdelfatah, S, Abdoli A, Abel S, Zanivan S, et al Guidelines for the use and interpretation of assays for monitoring autophagy (4th Edition). Autophagy 17(1):1-382, 2021. PMID: 33634751.
- Kay EJ, Koulouras G, Zanivan S Regulation of Extracellular Matrix Production in Activated Fibroblasts: Roles of Amino Acid Metabolism in Collagen Synthesis. Front Oncol 11(None):719922, 2021. PMID: 34513697.
- Santi A, Kugeratski FG, Zanivan S Cancer Associated Fibroblasts: The Architects of Stroma Remodeling. Proteomics 18(5-6):e1700167, 2018. PMID: 29280568.
- Hernandez-Fernaud JR, Reid SE, Neilson LJ, Zanivan S Quantitative mass spectrometry-based proteomics in angiogenesis. Proteomics Clin Appl 7(7-8):464-76, 2013. PMID: 23161605.
Selected Presentations & Talks
International Presentations
- 2025. "CAF metabolism and the immune-TME”. Invited. Keystone Symposium Tumor metabolism: environmental influences and therapeutic Vulnerabilities. Vancouver, CA.
- 2025. “Harnessing stroma-immune interactions for anti-cancer therapy”. Invited. Forbeck Cancer Forum. Pacific Grove, US.
- 2025. "CAF metabolism and the immune-TME”. Invited. International Society for Cancer Metabolism (ISCaM) Meeting 2025. Brussels, BE.
- 2024. "Harnessing CAF metabolism to create an anti-tumor microenvironment”. Invited. European Association for Cancer Research (EACR) Conference 'The Tumour Ecosystem: Cellular Interactions and Therapeutic Opportunities'. Bergamo, IT.
- 2024. “Redox proteomics for global analysis of oxidative response”. Invited. Benzon Foundation meeting Clinical Proteomics. Copenhagen, DK.
- 2024. “Modulating cell metabolism to build an anti-tumor stroma”. Invited. European Association for Cancer Research (EACR) Annual Congress. Rotterdam, NL.
- 2023. “Tinkering with CAF metabolism to establish an anti-tumor stroma”. Invited. 2nd international conference on Nanomedicine Meets the Tumor Microenvironment (NanoTME2023). Twente, NL.
- 2023. “Metabolic control of ECM production in tumors”. Invited. Collagen Gordon Research Conference. New London, US.
- 2023. “CAF metabolism coordinates tumor ECM production”. Invited. ASMB and ISMB e-Symposium. Virtual, US.
- 2023. “Harnessing CAF metabolism to establish an anti-tumor stroma”. Invited. 40th Anniversary ASEICA Congress. Coruna, ES.
- 2023. “Harnessing CAF metabolism to establish an anti-tumor stroma”. Invited. 4th Crick International Cancer Conference 2023. London, GB.
- 2023. “Harnessing CAF metabolism to create an anti-tumor stroma”. Invited. British Association for Cancer Research (BACR) meeting on Tumour Microenvironment, basic science, novel therapies. Nottingham, GB.
- 2023. Plenary Speaker: “Fibroblasts: bystander or culprit in cancer?”. Invited. European Proteomic Association (EuPA) & British Society for Proteome Research (BSPR) Annual International Meeting. Newcastle, GB.
- 2022. “CAF metabolism shapes the tumor microenvironment”. Invited. Structural microenvironment European Association for Cancer Research (EACR) Virtual Conference, GB.
- 2022. “Cell metabolism defines tumor-promoting functions of cancer associated fibroblasts”. Invited. Somatic Evolution and Tumour Microenvironment Symposium 2022, GB.
- 2022. "Cell metabolism coordinates the production of tumor promoting collagen in CAFs”. Invited. Advances Scleroderma Research Global Webinar. Virtual, US.
- 2022. Keynote Speaker: “Cell metabolism defines tumor-promoting functions of CAFs”. Invited. 4th Swedish Tumour Microenvironment Retreat. Baslta, CH.
- 2022. Keynote Speaker: “CAF metabolism drives pro-tumorigenic remodeling of the TME”. Invited. International Society of Cancer Metabolism: ISCaM 2022. Turin, IT.
- 2022. “CAF metabolism drives pro-metastatic remodeling of the TME”. Invited. 1st Aegean International Conference on ‘Mesenchymal cells in health and disease’. Crete, GR.
- 2022. Keynote Speaker: “MS redox proteomics for global analysis of oxidative response”. Invited. International Mass Spectrometry Conference (IMSC2022). Maastricht, NL.
- 2022. “CAF metabolism coordinates extracellular matrix production”. Invited. European Association for Cancer Research (EACR) Innovations in Cancer Metabolism: Mechanisms to Therapies. Bilbao, ES.
- 2021. “CAF metabolism coordinates ECM production”. Invited. Metabolism Meets Function – 3rd Edition. Virtual, IT.
- 2020. “MS proteomics to uncover the complexity and function of the cell secretome”. Invited. 22nd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy. Virtual, FR.
- 2019. "CAFs are key mediators of tumor-stroma interactions: role of extracellular vesicles”. Invited. British Society Proteome Research (BSPR) Annual meeting. Southampton, GB.
- 2018. “Breast cancer CAF metabolism: role of the pyruvate dehydrogenase”. Invited. Metabolism in Cancer and Stromal Cells. Leuven, BE.
- 2018. “CAF metabolism: role of the pyruvate dehydrogenase”. Invited. Beatson Cancer Conference. Glasgow, GB.
- 2017. “Modern mass spectrometry: how to use MS for quantitative and functional exploration of proteins and metabolites”. Invited. ASCB-EMBO Meeting. Philadelphia, US.
- 2017. “Using proteomics to explore the pro-invasive crosstalk between stroma and cancer cells”. Invited. Human Proteome Organization (HUPO) World Congress. Dublin, IE.
- 2016. Invited Speaker. Invited. CLIC Meeting. Bethesda, US.
- 2016. “CLIC3: a secreted redox enzyme that drives cell invasion”. Invited. European Association for Cancer Research (EACR) Annual meeting. Manchester, GB.
- 2014. Invited Speaker. Invited. Goettingen, DK.
- 2013. Invited Speaker. Invited. Beatson Cancer Conference. Glasgow, GB.
- 2012. Invited Speaker. Invited. International Society of Applied Cardiovascular Biology. London, GB.
- 2012. Invited Speaker. Invited. European Proteomic Association (EuPA) Annual Meeting. Glasgow, GB.
- 2012. Invited Speaker. Invited. Systems Biology Europe. Madrid, ES.
- 2011. Invited Speaker. Invited. EMBO Cancer Proteomics. Dublin, IE.
Grant & Contract Support
| Title: | High resolution molecular profiling platform to investigate the role of tumor microbiota in anti-tumor immunity |
| Funding Source: | UKRI Cross Research Council |
| Role: | Co-PI |
| Title: | Combining plasma redox-proteomics with machine learning for early detection of hepatocellular carcinoma |
| Funding Source: | Cancer Reasearch UK Early Detection Project |
| Role: | PI |
| Title: | Investigating Biomarkers for the Early Detection of Pancreatic Cancer in Genetically Engineered Mouse Models of New Onset Diabetes-Associated Ductal Adenocarcinoma |
| Funding Source: | Cancer Research UK Early Detection Project |
| Role: | Co-PI |
| Title: | Differential Expression of Bystander Transcriptomes for Mesothelioma Diagnosis: DEBiT-Meso |
| Funding Source: | British Lung Foundation |
| Role: | Co-I |
| Title: | Spatial Analysis of Cancer Associated Fibroblast Subtypes in High Grade Serious Ovarian Carcinoma |
| Funding Source: | Beatson Cancer Charity |
| Role: | Co-PI |
| Title: | CRUK Cancer Research Horizon-Industry drug discovery project |
| Funding Source: | Cancer Research UK |
| Role: | PI |
| Title: | Elucidating the role of pyruvate dehydrogenase as an epigenetic switch controller in the breast cancer stroma |
| Funding Source: | Breast Cancer Now |
| Role: | PI |
| Title: | Exploring deep plasma redox-proteome profiling for early detection of HCC |
| Funding Source: | Early Detection Primer Award |
| Role: | PI |
| Title: | Advanced Proteomic Facility |
| Funding Source: | Cancer Research UK Core Grant |
| Role: | PI |
| Title: | Characterization of MCF10DICS.com-iCAF xenograft for the study of the stromal influence on breast cancer development |
| Funding Source: | Breast Cancer Now Pilot Grant |
| Role: | PI |
| Title: | In depth proteomic profile of mammary normal and cancer-associated fibroblasts |
| Funding Source: | Breast Cancer Now Pilot Grant |
| Role: | PI |
| Title: | Tumor Microenvironment and Proteomics |
| Funding Source: | Cancer Research UK Core Grant |
| Role: | PI |
Patient Reviews
CV information above last modified January 29, 2025